Pharmacyclics has signed a five-year cooperative research and development agreement (CRADA) with National Cancer Institute (NCI) to develop PCI-32765 for the treatment of hematologic malignancies (blood cancer).
PCI-32765 is an orally active small molecule inhibitor of Bruton’s tyrosine kinase.
As per the agreement, NCI’s Division of Cancer Treatment and Diagnosis (DCTD) plans to sponsor Phase 1 and Phase 2 trials of PCI-32765.
Pharmacyclics Oncology Development vice-president Eric Hedrick said the CRADA allows them to broaden their knowledge of PCI-32765, based on clinical trials to be performed by leading investigators in the field of hematologic malignancies.
Pharmacyclics is currently evaluating PCI-32765 in several Phase 2 clinical trials.
